Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue

Author(s): Ludimila Cavalcante, David P. Kelsen, Kenneth H. Yu

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 42 , 2014

Become EABM
Become Reviewer
Call for Editor


Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.

Keywords: Pancreatic adenocarcinoma, chemoradiotherapy, review.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [6697 - 6701]
Pages: 5
DOI: 10.2174/1381612820666140826154724
Price: $65

Article Metrics

PDF: 24